Urology · 2025
Survival Outcomes and Temporal Trends of Non-Surgical Management Vs Radical Cystectomy in Non-Organ-Confined Urothelial Bladder Cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Longoni Mattia, Rodriguez Peñaranda Natali, Marmiroli Andrea, Falkenbach Fabian, Le Quynh Chi, Nicolazzini Michele, Catanzaro Calogero, Tian Zhe, Goyal Jordan A, Puliatti Stefano, De Cobelli Ottavio, Graefen Markus, Chun Felix K H, Palumbo Carlotta, Schiavina Riccardo, Saad Fred, Shariat Shahrokh F, Moschini Marco, Gandaglia Giorgio, Montorsi Francesco, Briganti Alberto, Karakiewicz Pierre I
Аннотация
OBJECTIVE: To investigate whether bimodal therapy (BMT) or trimodal therapy (TMT) differ from radical cystectomy (RC) + perioperative chemotherapy (CT) in cancer control outcomes among patients with non-organ-confined (NOC; T3-4 and/or N1-3) urothelial carcinoma of the urinary bladder (UCUB).
METHODS: Within the Surveillance, Epidemiology, and End Results database (2005-2021), rates of BMT vs TMT vs RC + CT use in NOC UCUB patients were tabulated. Nearest-neighbor 1:1 propensity score matching (PSM) for age, sex, stage, and race/ethnicity was applied. Cumulative incidence plots depicted 5-year cancer-specific (CSM) and other-cause mortality (OCM) rates. Univariable and multivariable competing risks regression (CRR) models were fitted. Sensitivity analyses focused within T3-4,N0 patients.
RESULTS: Of 7401 NOC UCUB patients, 1645 (22.2%) received BMT vs 884 (11.9%) TMT vs 4872 (65.8%) RC+CT. Over the study period, BMT and TMT rates have not significantly changed. After PSM, the five-year CSM rate was 66.2% after BMT vs 44.9% after RC + CT and BMT was associated with 2.1-fold higher CSM relative to RC + CT (multivariable HR [mHR]: 2.12, P <.001). After PSM, 5-year CSM rates was 61.1% after TMT vs 46.6% after RC and TMT was associated with 1.6-fold higher CSM relative to RC (mHR: 1.63, P <.001). Virtually the same findings were found within T3-4,N0 patients.
CONCLUSION: Approximately three out of ten NOC UCUB patients were treated with either BMT or TMT. However, such practice was invariably associated with higher CSM relative to RC + CT. These observations should be discussed at clinical decision-making and prior to informed consent.
METHODS: Within the Surveillance, Epidemiology, and End Results database (2005-2021), rates of BMT vs TMT vs RC + CT use in NOC UCUB patients were tabulated. Nearest-neighbor 1:1 propensity score matching (PSM) for age, sex, stage, and race/ethnicity was applied. Cumulative incidence plots depicted 5-year cancer-specific (CSM) and other-cause mortality (OCM) rates. Univariable and multivariable competing risks regression (CRR) models were fitted. Sensitivity analyses focused within T3-4,N0 patients.
RESULTS: Of 7401 NOC UCUB patients, 1645 (22.2%) received BMT vs 884 (11.9%) TMT vs 4872 (65.8%) RC+CT. Over the study period, BMT and TMT rates have not significantly changed. After PSM, the five-year CSM rate was 66.2% after BMT vs 44.9% after RC + CT and BMT was associated with 2.1-fold higher CSM relative to RC + CT (multivariable HR [mHR]: 2.12, P <.001). After PSM, 5-year CSM rates was 61.1% after TMT vs 46.6% after RC and TMT was associated with 1.6-fold higher CSM relative to RC (mHR: 1.63, P <.001). Virtually the same findings were found within T3-4,N0 patients.
CONCLUSION: Approximately three out of ten NOC UCUB patients were treated with either BMT or TMT. However, such practice was invariably associated with higher CSM relative to RC + CT. These observations should be discussed at clinical decision-making and prior to informed consent.